Pieris Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 4, 2021 7:00 AM

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, AUGUST 4, 2021 AT 8:00 AM EDTAnnounced inhaled program PRS-220 for the treatment of IPF and was selected to receive a Bavarian government grant of approximately $17 million to evaluate the program for post-COVID pulmonary fibrosisSigned respiratory and ophthalmology agreement with Genentech with a $20 million upfront payment and more than $1.4 billion in potential additional milestone...

Read more

Apollo Endosurgery, Inc. Reports Record Endoscopy Revenue in Second Quarter, Raises Full-Year Outlook Conference Call to Discuss Results Today at 3:30 p.m. CT / 4:30 p.m. ET

August 3, 2021 4:01 PM

AUSTIN, TX / ACCESSWIRE / August 3, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended June 30, 2021.HighlightsAchieved total revenue of $16.6 million, an increase of 194% compared to the second quarter of 2020, and a new revenue record for the Company*Increased Endoscopic Suturing...

Read more

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

August 3, 2021 8:05 AM

- Goal of FDA Breakthrough Device Program is to speed up development by giving priority to devices that treat life-threatening or irreversibly debilitating conditions- Company preparing to begin SAVVE U.S. pivotal trial for VenoValve- VenoValve is a potential treatment for approximately 2.4 million U.S. patients that suffer from severe Chronic Venous Insufficiency in the deep veins of their legsIRVINE, CA / ACCESSWIRE / August 3, 2021 / Hancock...

Read more

Pieris Pharmaceuticals Strengthens Executive R&D Leadership Team

August 3, 2021 8:00 AM

Tim Demuth, M.D., Ph.D., joins Pieris as Chief Medical OfficerShane Olwill, Ph.D., promoted to Chief Development OfficerBOSTON, MA / ACCESSWIRE / August 3, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the appointment of Tim Demuth, M.D.,...

Read more

EV Biologics NFT Dividend Warrant Date

July 30, 2021 9:00 AM

NASHVILLE, TN / ACCESSWIRE / July 30, 2021 / EV Biologics Corp., OTC PINK:YECO, today confirmed for share holders its NFT Warrant Dividend shareholders-of-record date.YECO's shareholders-of-record on July 30, 2021 will receive the Warrant. The Company advises shareholders to be certain to hold their shares for at least several days thereafter to ensure their name is on the DTC list. Shareholders possessing less than 100 shares will not be...

Read more

Dyadic to Report Second Quarter 2021 Financial Results

July 29, 2021 4:30 PM

JUPITER, FL / ACCESSWIRE / July 29, 2021 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it will report its...

Read more

ReShape Lifesciences to Report Second Quarter 2021 Financial and Operational Results on Thursday, August 5, 2021

July 29, 2021 8:30 AM

Webinar will be available discussing recent major milestones that same daySAN CLEMENTE, CA / ACCESSWIRE / July 29, 2021 / ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company is scheduled to release its second quarter financial results on Thursday, August 5, 2021, before the financial markets open."We look forward to announcing our significant...

Read more

Applied UV, Inc. Announces Full Exercise of Over-Allotment Option

July 29, 2021 8:00 AM

MOUNT VERNON, NY / ACCESSWIRE / July 29, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection prevention technology company that applies the power of narrow-range ultra violet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, today announced the that the underwriters of its 10.5% Series A Cumulative Perpetual Preferred Stock (the "Series A Preferred Stock") have exercised in full their...

Read more

Enzolytics Reports Its Progress Toward Completion Of Clinical Trials for Its ITV-1 ANTI-HIV Therapeutic and Securing Use Authorization Under the European Medicines Agency

July 29, 2021 7:30 AM

COLLEGE STATION, TX / ACCESSWIRE / July 29, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (http://enzolytics.com/) has completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic Design (https://clinicdesign.eu/) to advance its anti-HIV therapeutic ITV-1 to production and clinical trials. These steps are prefatory to approval by the European Medicines Agency (EMA), leading to patient use authorization.Production of the...

Read more

Lexaria's DehydraTECH-CBD Lowers Blood Pressure

July 29, 2021 7:05 AM

Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerabilityKELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is extremely pleased to issue partial results from human clinical study HYPER-H21-1 evaluating DehydraTECHTM-processed cannabidiol ("CBD") for...

Read more

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

July 28, 2021 2:00 PM

FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today announced the closing of its previously announced private placement with a single healthcare-focused institutional investor for 4,629,630 shares of its common...

Read more

EV Biologics Starts Custom Cell Isolation with Lonza Cell Bio Services

July 28, 2021 9:00 AM

NASHVILLE, TN / ACCESSWIRE / July 28, 2021 / EV Biologics Corp, OTC PINK:YECO today announced that it has signed an agreement with Lonza Cell Bio Services to implement a custom cell isolation in preparation for a novel, clonal, master cell bank. These cells will also be used in optimization of the process for production of therapeutically active, native, extracellular vesicles and particles (EVP).Lonza Cell Bio Services is a leading provider of...

Read more

Green Planet Projects Major Increase in Revenues

July 28, 2021 9:00 AM

PHOENIX, AZ / ACCESSWIRE / July 28, 2021 / Green Planet Group, Inc. (OTC PINK:GNPG), an emerging leader in green technology, announced today that its wholly owned subsidiary, XenTx Lubricants' Nigerian international distributor, FirstHypo Tech Ltd, has obtained government required approvals to sell seven of the XenTx products in its country. The Federal Ministry of Trade and Investment issued the Trademark Acceptance Letters on July 11,...

Read more

Pieris Pharmaceuticals to Host Second Quarter 2021 Investor Call and Provide Corporate Update on August 4, 2021

July 28, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / July 28, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a second quarter 2021 investor call on Wednesday, August 4, 2021 at 8:00 AM EDT to discuss financial results and provide a corporate update.To...

Read more

ITOCO Welcomes Mr. Alberto Ramirez As the Leader of Its Technical Management Team, Carbon Credits

July 28, 2021 8:00 AM

TORONTO, ON / ACCESSWIRE / July 28, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce that Mr. Alberto Ramirez has joined the firm as leader of Technical Management Team, Carbon Credits and Capture.Mr. Ramirez is a Biologist and graduated from the National Autonomous University of Mexico. He came to Itoco from the World Resources Institute (WRI) - Mexico, where he is the Forest Carbon Coordinator.He was responsible for coordinating Carbon...

Read more

DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores

July 28, 2021 7:05 AM

Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many moreKELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its DehydraTECHTM technology has been embraced by consumer brands now available for sale in over 7,000 stores across the US."Lexaria's...

Read more

Materna Medical Raises $10 Million in Series A2 Funding in Women's Health

July 27, 2021 12:21 PM

Growing novel OBGYN platform company that defines a $6B market in the most common pelvic conditions women faceMOUNTAIN VIEW, CA / ACCESSWIRE / July 27, 2021 / Materna Medical (Materna), a clinical-stage medical device company, has announced the completion of a $10 million Series A2 financing round. The round was led by Wavemaker Three-Sixty Health (Wavemaker 360) with new investors including Kimera Limited, Women's Venture Capital Fund, Golden...

Read more

ITOCO Welcomes Mr. Rene A. Ibarra to its Technical Management Team, Carbon Credits

July 27, 2021 10:15 AM

TORONTO, ON / ACCESSWIRE / July 27, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to announce that Mr. Rene Ibarra has joined the firm's Technical Management Team, Carbon Credits and Capture.Previously, he has been accredited as a leading verifier by the Climate Action Reserve to verify Carbon Capture projects under the standard of the Mexico Forest Protocol since 2016, participating in the evaluation of 48 projects developed in the State of...

Read more

Apollo Endosurgery to Report Second Quarter Financial Results on August 3, 2021

July 27, 2021 8:00 AM

AUSTIN, TX / ACCESSWIRE / July 27, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its financial results for the second quarter ended June 30, 2021 on Tuesday, August 3, 2021 after the market closes. In conjunction with the release, Apollo will host a conference...

Read more

Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2

July 27, 2021 7:15 AM

Additionally, second patent award received in JapanKELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has been completed in its second human clinical study of 2021.Human clinical study HYPER-H21-2 consisted of 16 human volunteers who were pre- or mildly hypertensive and received three...

Read more